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COMMENTARY
The strategies of alcohol industry SAPROs: Inaccurate information,
misleading language and the use of confounders to downplay and
misrepresent the risk of cancer
We start by summarising our core ﬁndings, to contex-
tualise the rest of our response. These are that alcohol
industry social aspects/public relations organisations
(SAPRO) dispute in different ways the risk of cancer
from alcohol consumption, particularly breast cancer,
and to some extent colorectal cancer [1]. When some
risk is acknowledged, that risk is often presented in
conjunction with a range of other potential con-
founders, thus undermining the evidence that there is
an independent relationship. Smoking is sometimes
used to imply that the risk is conﬁned to smokers. Not
all these strategies are used by all these (or other)
SAPROs, all the time.
Several of the responses to our paper state that the
relevant organisation does, in fact, include accurate
information about cancer on their websites or docu-
ments, along with explicit statements about increased
risk. We did not claim that all the information on these
websites is inaccurate or misleading. In fact, in many
cases accurate information is included, while at the
same time inaccurate information is presented else-
where. Thus, accurate information may be framed in
such a way that it is simultaneously undermined. For
example, Éduc’alcool’s publication ‘Alcohol and
Women’ does have a clear statement about the risk of
breast cancer, as they say in their letter. However this
needs to be seen alongside their inaccurate statement
(which we cited) that ‘no causal relationship has been
shown between moderate drinking and breast cancer’. Pre-
senting a mix of accurate and misleading or distracting
information potentially sows doubt about the well-
evidenced relationship between alcohol consumption
and cancer.
One justiﬁcation made by SAPROs for presenting
information about a host of confounders is that it is
their duty to present a complete picture about alcohol
and health. We think that this is a weak justiﬁcation for
proffering a range of generic advice about unmodiﬁ-
able confounders, hormone environments, genetic
risks, ageing and so on. It is doubtful that the public
turns to such websites for generic lifestyle information,
or information about childbirth, or breastfeeding. The
argument we made in the paper is that the inclusion of
a wide range of potential confounders, and risk/protec-
tive factors, has similarities to well-documented
tobacco industry strategies. These involved highlight-
ing the complexity of the aetiology of lung cancer and
coronary heart disease, thereby undermining the epide-
miological evidence of a clear, independent
relationship.
Our analysis also highlighted the selective omission
of breast cancer from some SAPRO materials. The
Drinkaware Fact sheet ‘Alcohol and Young people’
stated (in a section headed ‘Liver Disease’) that ‘In the
long-term, drinking above the lower-risk guidelines
can also lead to cancers, such as bowel and liver can-
cer, heart disorders and impotence for men’, without
mentioning breast cancer. The opening sentences of
their ‘Alcohol and Cancer’ fact sheet (both factsheets
downloaded in August 2016) also appears to empha-
sise uncertainty, without actually mentioning alcohol:
“There is no scientiﬁc consensus on why some peo-
ple develop cancer and others don’t. Your genes and
your lifestyle choices interact, and together they
make up your risk of developing cancer.”
The Drinkaware example is one example which we
cited in relation to confounding, but it is not (contrary
to their letter) the only example we included from this
body (See Table 3: ‘Light to moderate drinking is associ-
ated with minimally increased risk of overall cancer. For
men who have never smoked, risk of alcohol related cancers
is not appreciably increased for light and moderate drinking
(up to two drinks per day’).
This is also relevant to the International Alliance for
Responsible Drinking (IARD) response, which rejects
our ﬁnding that they deny that alcohol causes at least
one type of cancer. IARD does indeed explicitly point
to a link between drinking and cancer. However, as we
showed, it also provides information which may be
misleading to readers, including stating that there is no
increase in risk associated with ‘light or moderate’
drinking, that the increased risk is ‘in general
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associated with heavy drinking’ (undeﬁned), or where
it appears to imply that alcohol is protective of colorec-
tal cancer in smokers [1]. In response to the point
about mechanisms, we coded references in the IARD
documents to ethanol, acetaldehyde, and in other
places, the role of genetics, and hormone receptor sta-
tus as potential mechanisms by which alcohol may
affect cancer. In the case of hormone receptor status,
the mechanism is unclear [2], as stated in the IARD
document, but as we noted in our paper, the discus-
sion of unclear mechanisms appears to undermine
clearer statements about risk.
The letter from the Portman Group explains further
their statement that ‘the vast majority of cancer types are
not associated with alcohol consumption’. This is worth
highlighting, as this argument increasingly appears in
other alcohol industry-related contexts also. The state-
ment is indeed accurate, but in the context of discus-
sion of the risk of cancer from alcohol, meaningless. It
is also highly misleading, for the reasons we raise in
the paper (i.e. it conﬂates cancer type with cancer
prevalence). As they say, the table in their document
does indeed present information on cancer prevalence.
However their quote (cited above) does not. To under-
stand why this is misleading, it may be worth consider-
ing what an equivalent argument would look like in the
case of tobacco, where a statement like ‘most cancer
types are not caused by smoking’ would be considered to
be highly misleading, at best.
The Portman Group response also rejects our state-
ment that there is no discussion of colorectal cancer, by
pointing out that it appears in the table in their docu-
ment. It does indeed appear in that table, but there is no
discussion of the risk of colorectal cancer in the ‘cancer’
section of their document. Where this cancer is men-
tioned in Section 8.11 of the document, the increased
risk appears to be rejected in the section which immedi-
ately follows. This begins (incorporating an external
quote)—‘However…as for cancer, studies show that for
light regular drinkers, the risk is non-existent or minimally
increased. The exception is breast cancer…’. It then goes on
to claim that the increased breast cancer risk only
applies to women who binge drink, have a low folate
intake, or are on hormone replacement therapy. In
effect, the Portman document ﬁrst quotes the Chief
Medical Ofﬁcer’s statement about increased risk of a
range of cancers, including bowel cancer, and then
rejects it in the subsequent paragraph. It is true however
that the document we included is the Portman Group’s
technical response to the public consultation on the
revised UK Chief Medical Ofﬁcer guidelines. We think
it is more than reasonable to include this as it is a signiﬁ-
cant publicly-available statement on alcohol and cancer
from a leading alcohol industry SAPRO, and a
document which was intended to feed directly into pub-
lic guidance on safer alcohol consumption.
The Portman Group letter also notes that we incor-
rectly attributed a quote from Hoek and Zakhari
(2014) to the Portman Group. This is true and we are
happy to make clear that this quote is part of a Port-
man Group argument (that is, it is not the Portman
Group’s own quote—they are using it to support their
argument). Their letter also appears to dispute our
point about their referencing of independent scientiﬁc
reviews, pointing out that they cite International
Agency for Research on Cancer reviews, for example.
Our key point here (as we said in our paper) was that
in the section relating to breast cancer, the Portman
Group document does not reference the International
Agency for Research on Cancer reviews, other system-
atic reviews, nor the Committee on Carcinogenicity
review [3].
In short, while we welcome the minor corrections
some of these bodies have made, the ﬁndings and con-
tribution of this research remain unchanged. Our anal-
ysis builds on existing evidence regarding the activities
of SAPROs [4–6], and their clear similarities to
tobacco industry tactics, reﬂecting the inherent conﬂict
of interest. Our ﬁndings also show that we need to
consider carefully not only the accuracy of that infor-
mation, but also its contextualisation.
Finally, we are surprised at Drinkaware’s statement
that our analysis is ‘unprofessional’. On the contrary,
we consider that the analysis of cancer information
disseminated by alcohol industry SAPROs, and the
analysis of its accuracy and framing, is not only a pro-
fessional necessity for public health experts, but is also
essential, given the potential impact of such informa-
tion on the public. Independent professional organisa-
tions should welcome such analysis, and we welcome
the fact that some of the SAPROs appear to have cor-
rected some of their online material.
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